Wanbury Share Price Today (WANBURY)
TODAY IN ONE LINE
WANBURY slumped 5.1% on above-average volume (2.6x avg), lagging Nifty's -0.0% move, supported by recent strong earnings.
With a market cap of ₹1,091.16 Cr., it trades at a P/E of N/A. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Wanbury flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Quarterly OutperformanceLatest quarter Sales up 24.5% and Profit up 1197.0%
- ●High Capital EfficiencyROCE of 36.6% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 76.5%
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.03x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Rising Receivables vs SalesReceivables grew 25.8% outpacing sales growth of 4.1%
Latest Wanbury News
What changed recently?
Recent events, corporate actions, and announcements.
Wanbury Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Wanbury Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Wanbury Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Wanbury Ltd — derived from the live tape, not yesterday's close.
Wanbury Ltd last traded at ₹312.45 with an intraday range of ₹310.2–₹331.7 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹312.45| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 369.03 | +56.58 | +18.11% |
| R3 | 347.53 | +35.08 | +11.23% |
| R2 | 339.62 | +27.17 | +8.69% |
| R1 | 326.03 | +13.58 | +4.35% |
| PIVOT | 318.12 | 5.67 | 1.81% |
| CURRENT | 312.45 | — | — |
| S1 | 304.53 | -7.92 | -2.53% |
| S2 | 296.62 | -15.83 | -5.07% |
| S3 | 283.03 | -29.42 | -9.41% |
| S4 | 261.53 | -50.92 | -16.30% |
WANBURY is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹326.3–₹331.7
Trading Below opening range, showing Bearishness
Wanbury Ltd financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Wanbury Ltd — consolidated or standalone — with margins, YoY growth and key ratios inline.
Wanbury Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹1,091.16 Cr. and reported EPS of ₹13.10.
| Metric | Mar 2024 | Mar 2025 |
|---|---|---|
| Revenue from Operations | 576 | 600 ▲ 4.1% |
| Sales Growth YoY %Derived | 15.21% | 4.15% |
| Other Income | 3 | 3 ▲ 16.8% |
| Total Income | 579 | 603 ▲ 4.2% |
| 303 | 294 ▼ 2.7% | |
| Gross ProfitDerived | 273 | 305 ▲ 11.7% |
| Gross Margin %Derived | 47.43% | 50.88% |
| 203 | 229 ▲ 12.7% | |
| EBITDA (Operating Profit)Derived | 70 | 76 ▲ 9.0% |
| OPM %Derived | 12.16% | 12.73% |
| 68 | 50 ▼ 25.8% | |
| Profit Before Tax (PBT) | 56 | 30 ▼ 47.5% |
| 0 | -1 ▼ 357.1% | |
| Effective Tax %Derived | 0.68% | -3.31% |
| Total Profit for Period | 56 | 31 ▼ 45.4% |
| Net Profit (Owner's PAT)Derived | 56 | 31 ▼ 45.4% |
| Net Profit Margin %Derived | 9.72% | 5.09% |
| PAT Growth YoY %Derived | 638.26% | -45.44% |
| Earnings Per Share (EPS ₹) | 17.09 | 9.32 ▼ 45.5% |
| Diluted Shares Outstanding (Cr) | 3 | 3 ▲ 0.1% |
| Other Comprehensive Income (Net of Tax) | -1 | -0 ▲ 48.0% |
| Total Expenses (incl. D&A & Interest) | 522 | 573 ▲ 9.8% |
| Material Cost % of RevenueDerived | 50.24% | 46.35% |
| Employee Cost % of RevenueDerived | 15.10% | 17.39% |
| Other Cost % of RevenueDerived | 20.17% | 20.76% |
| Interest Coverage (x)Derived | 1.95x | 1.71x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 374 | 374 ▼ 0.2% | 367 ▼ 1.6% | 393 ▲ 6.8% | 511 ▲ 30.2% | 500 ▼ 2.3% | 576 ▲ 15.2% | 600 ▲ 4.1% | |
| Sales Growth YoY %Derived | — | -0.15% | -1.65% | 6.82% | 30.23% | -2.26% | 15.21% | 4.15% | |
| Other Income | 76 | 77 ▲ 0.7% | 1 ▼ 98.5% | 2 ▲ 110.9% | 2 ▼ 37.3% | 1 ▼ 39.4% | 3 ▲ 227.4% | 3 ▲ 16.8% | |
| Total Income | 450 | 450 ▲ 0.0% | 369 ▼ 18.1% | 395 ▲ 7.1% | 513 ▲ 29.8% | 501 ▼ 2.4% | 579 ▲ 15.6% | 603 ▲ 4.2% | |
174 | 174 ▼ 0.0% | 176 ▲ 0.9% | 217 ▲ 23.6% | 300 ▲ 38.3% | 303 ▲ 0.8% | 303 ▲ 0.0% | 294 ▼ 2.7% | ||
| Gross ProfitDerived | 200 | 200 ▼ 0.3% | 192 ▼ 3.9% | 175 ▼ 8.5% | 211 ▲ 20.3% | 197 ▼ 6.6% | 273 ▲ 38.5% | 305 ▲ 11.7% | |
| Gross Margin %Derived | 53.47% | 53.40% | 52.17% | 44.68% | 41.26% | 39.44% | 47.43% | 50.88% | |
268 | 267 ▼ 0.0% | 168 ▼ 37.1% | 157 ▼ 6.5% | 176 ▲ 11.6% | 174 ▼ 1.0% | 203 ▲ 16.8% | 229 ▲ 12.7% | ||
| EBITDA (Operating Profit)Derived | -67 | -68 ▼ 0.7% | 23 ▲ 134.5% | 18 ▼ 23.1% | 35 ▲ 96.0% | 23 ▼ 34.4% | 70 ▲ 202.1% | 76 ▲ 9.0% | |
| OPM %Derived | -18.04% | -18.18% | 6.38% | 4.59% | 6.91% | 4.64% | 12.16% | 12.73% | |
41 | 41 ▲ 0.3% | 125 ▲ 204.1% | 33 ▼ 73.8% | 108 ▲ 230.3% | 33 ▼ 69.4% | 68 ▲ 104.2% | 50 ▼ 25.8% | ||
| Profit Before Tax (PBT) | -32 | -32 ▲ 0.0% | 65 ▲ 299.7% | -12 ▼ 119.2% | 81 ▲ 754.0% | -10 ▼ 112.7% | 56 ▲ 647.7% | 30 ▼ 47.5% | |
-0 | -0 ▼ 0.0% | 0 ▲ 155.3% | 0 ▼ 4.2% | -0 ▼ 273.1% | 0 ▲ 131.5% | 0 ▲ 249.5% | -1 ▼ 357.1% | ||
| Effective Tax %Derived | 1.17% | 1.17% | 0.32% | -1.61% | -0.43% | -1.06% | 0.68% | -3.31% | |
| Total Profit for Period | -32 | -32 ▲ 0.0% | 64 ▲ 301.4% | -13 ▼ 119.6% | 81 ▲ 746.3% | -10 ▼ 112.8% | 56 ▲ 638.3% | 31 ▼ 45.4% | |
| Net Profit (Owner's PAT)Derived | -32 | -32 ▲ 0.0% | 64 ▲ 301.4% | -13 ▼ 119.6% | 81 ▲ 746.3% | -10 ▼ 112.8% | 56 ▲ 638.3% | 31 ▼ 45.4% | |
| Net Profit Margin %Derived | -8.55% | -8.57% | 17.54% | -3.21% | 15.94% | -2.08% | 9.72% | 5.09% | |
| PAT Growth YoY %Derived | — | 0.00% | 301.39% | -119.56% | 746.33% | -112.76% | 638.26% | -45.44% | |
| Earnings Per Share (EPS ₹) | -13.49 | -13.49 ▲ 0.0% | 25.79 ▲ 291.2% | -5.04 ▼ 119.5% | 24.94 ▲ 594.8% | -3.18 ▼ 112.8% | 17.09 ▲ 637.4% | 9.32 ▼ 45.5% | |
| Diluted Shares Outstanding (Cr) | 2 | 2 ▲ 0.0% | 2 ▲ 5.4% | 3 ▲ 0.1% | 3 ▲ 30.6% | 3 ▲ 0.1% | 3 ▲ 0.1% | 3 ▲ 0.1% | |
| Other Comprehensive Income (Net of Tax) | 0 | 0 ▲ 0.0% | -0 ▼ 214.2% | -0 ▼ 3.7% | 1 ▲ 370.7% | 0 ▼ 90.9% | -1 ▼ 802.8% | -0 ▲ 48.0% | |
| Total Expenses (incl. D&A & Interest) | 483 | 483 ▼ 0.0% | 304 ▼ 37.0% | 407 ▲ 34.0% | 432 ▲ 6.0% | 511 ▲ 18.4% | 522 ▲ 2.2% | 573 ▲ 9.8% | |
| Material Cost % of RevenueDerived | 34.33% | 34.38% | 39.85% | 54.44% | 59.65% | 51.53% | 50.24% | 46.35% | |
| Employee Cost % of RevenueDerived | 23.34% | 23.37% | 18.36% | 16.34% | 14.63% | 16.21% | 15.10% | 17.39% | |
| Other Cost % of RevenueDerived | 48.17% | 48.21% | 27.43% | 23.75% | 19.71% | 18.59% | 20.17% | 20.76% | |
| Interest Coverage (x)Derived | -2.53x | -2.53x | 0.42x | 0.36x | 1.16x | 0.50x | 1.95x | 1.71x |
Wanbury segment analysis : revenue and profit mix.
Disclosed business segments at Wanbury with their share of revenue and profit, switchable between consolidated and standalone reporting.
Wanbury discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Wanbury Ltd.
Our AI distills the core fundamental drivers supporting Wanbury Ltd, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Wanbury Ltd's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
High ROE of 76.50% and ROCE of 36.60% significantly exceed peer medians.
Vertical integration of APIs and formulations reduces supply chain costs effectively.
Operating margin of 14.22% supports solid profitability in competitive pharma sector.
Low debt-to-equity ratio of 0.0302 reflects conservative financial leverage management.
Promoter holding of 43% ensures aligned governance and long-term strategic focus.
Key Risks.
TTM revenue declined 19.2% YoY, signaling weakening top-line momentum and demand.
Quarterly profit variance of 1197% indicates extreme earnings volatility and unpredictability.
Negative free cash flow of ₹247.74 Cr in latest quarter threatens liquidity sustainability.
Zero dividend yield offers no income to shareholders seeking regular returns.
High beta of 1.23 exposes investors to significant price volatility and downside risk.
Flip Conditions.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 3.52. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 72% would indicate weaker capital compounding.
Wanbury Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Wanbury Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Wanbury Ltd chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Wanbury Ltd — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Wanbury Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Wanbury Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Wanbury Ltd stood at 60.5% of traded volume, against a 20-day average of 42.7%.
Wanbury announcements: results, concalls, ratings, M&A.
Filings Wanbury sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Wanbury files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 73 documents below.
General Updates
Wanbury Limited has informed the Exchange about General Updates
General Updates
Wanbury Limited has informed the Exchange about General Updates
Price movement
Significant movement in price has been observed in Wanbury Limited. The Exchange, in order to ensure that investors have latest relevant information…
Price movement
Significant movement in price has been observed in Wanbury Limited. The Exchange, in order to ensure that investors have latest relevant information…
General Updates
Wanbury Limited has informed the Exchange about General Updates
Investor decks & rating reports.
Wanbury dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Wanbury has declared, sequenced by announce and record date.
Wanbury corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Wanbury Ltd: business, sector, key facts.
What Wanbury Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Wanbury Ltd operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: WANBURY, BSE: 524212.
Wanbury Limited is a pharmaceutical company based in Navi Mumbai, India, established in 1988 (formerly known as Pearl Organics Limited). The company's core business is the manufacturing and sale of both pharmaceutical formulations and active pharmaceutical ingredients (APIs). This dual approach allows for vertical integration within their supply chain, potentially increasing efficiency and control over product quality and cost.
Wanbury's formulations cater to a broad range of therapeutic areas. Their product portfolio includes medications for gynecological conditions, orthopedic issues, hematological disorders (related to blood), diabetes, gastrointestinal problems, stroke recovery, and common ailments like coughs and colds. Additionally, they offer formulations addressing pain (analgesics), inflammation (anti-inflammatories), and other general practitioner needs. The diversification across therapeutic areas likely reflects a strategy to mitigate risk and tap into various market segments.
Complementing their formulations business, Wanbury also produces a significant range of APIs. These are the fundamental chemical compounds used to create finished pharmaceutical products. Wanbury's API production focuses on key therapeutic areas, including diabetes (anti-diabetic APIs), pain relief (anti-analgesic APIs), depression (anti-depressant APIs), allergies (anti-histaminic APIs), inflammation and arthritis (anti-inflammatory and anti-arthritis APIs), blood clotting disorders (anti-thrombotic APIs), epilepsy (anti-epileptic APIs), and high blood pressure (anti-hypertensive APIs). This API production provides a strong foundation for their own formulations and also allows them to potentially supply other pharmaceutical companies.
In summary, Wanbury's business model integrates both the manufacturing of formulations for direct sale and the production of APIs, a crucial component in the pharmaceutical industry's supply chain. Their extensive product portfolio targeting diverse therapeutic areas demonstrates a strategy for market diversification and sustained growth. Their presence both domestically in India and internationally positions them within a global pharmaceutical landscape.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Top Losers TodayScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Wanbury Ltd (WANBURY).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Wanbury Ltd (WANBURY)?
The current share price of Wanbury Ltd (WANBURY) is ₹312.45. Today, the stock has declined by ₹16.80 (5.10%), trading in a range of ₹310.2 to ₹331.7. The stock opened at ₹330 with a trading volume of 2,85,158 shares.
02Is Wanbury Ltd stock a good investment for long-term?
Wanbury Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1,091.16 crores, P/E ratio of 0.00, ROE of 76.50%, and ROCE of 36.60%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Wanbury Ltd stock?
The 52-week high price of Wanbury Ltd (WANBURY) is ₹358.85, while the 52-week low is ₹161.5. Currently trading at ₹312.45, the stock is 76.5% away from its 52-week low and 12.9% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Wanbury Ltd stock at the current price?
Whether to buy Wanbury Ltd stock at ₹312.45 depends on multiple factors. The stock is currently trading with a P/E ratio of 0.00 and P/B ratio of 0.00. Today's performance shows a loss of 5.10%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Wanbury Ltd and when is the next dividend?
Wanbury Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹312.45, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Wanbury Ltd?
Wanbury Ltd's key financial metrics include: P/E Ratio: 0.00, P/B Ratio: 0.00, ROE: 76.50%, ROCE: 36.60%, Dividend Yield: 0.00%, EPS: ₹13.10, Book Value: ₹18.1, and Debt-to-Equity: 3.02. The company's market cap stands at ₹1,091.16 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Wanbury Ltd stock performing today in the market?
Wanbury Ltd stock opened at ₹330 and is currently trading at ₹312.45, showing a decline of ₹16.80 (5.10%). The intraday high is ₹331.7 and low is ₹310.2. The trading volume stands at 2,85,158 shares, indicating moderate market participation today.
08What is the P/E ratio of Wanbury Ltd and what does it indicate?
Wanbury Ltd has a Price-to-Earnings (P/E) ratio of 0.00, which means investors are willing to pay ₹0.00 for every ₹1 of earnings. With an EPS of ₹13.10, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Wanbury Ltd (WANBURY) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.